We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+7.86%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$477M
AUM Growth
+$65.8M
Cap. Flow
+$35.2M
Cap. Flow %
7.38%
Top 10 Hldgs %
62.53%
Holding
49
New
12
Increased
8
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$24.1M
2
LLY icon
Eli Lilly
LLY
+$23.5M
3
BSX icon
Boston Scientific
BSX
+$23.2M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$18.9M
5
SLNO
Soleno Therapeutics
SLNO
+$18.6M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$46.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$33.5M
3
VCYT icon
Veracyte
VCYT
+$22.6M
4
LIVN icon
LivaNova
LIVN
+$15M
5
INSP icon
Inspire Medical Systems
INSP
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SEPN
26
Septerna Inc
SEPN
$1.75B
$3.11M 0.65%
294,360
-729,885
-71% -$6.01M
REPL icon
27
Replimune Group
REPL
$1.01B
$3.07M 0.64%
330,337
-25,303
-7% -$221K
ZBIO
28
Zenas BioPharma
ZBIO
$2.05B
$2.09M 0.44%
215,314
-79,834
-27% -$777K
VIR icon
29
Vir Biotechnology
VIR
$1.49B
$1.96M 0.41%
388,303
-223,305
-37% -$1.2M
KYTX icon
30
Kyverna Therapeutics
KYTX
$484M
$1.8M 0.38%
586,909
– –
IRON icon
31
Disc Medicine
IRON
$2.97B
$1.62M 0.34%
+30,661
New +$1.44M
FULC icon
32
Fulcrum Therapeutics
FULC
$297M
$1.3M 0.27%
188,304
-13,835
-7% -$74K
BCAX
33
Bicara Therapeutics
BCAX
$1.84B
$909K 0.19%
+97,800
New +$1.17M
MGX icon
34
Metagenomi Therapeutics
MGX
$46.3M
$783K 0.16%
528,993
– –
KPTI icon
35
Karyopharm Therapeutics
KPTI
$48M
$629K 0.13%
146,013
-9,609
-6% -$47.1K
HYPR icon
36
Hyperfine
HYPR
$101M
$547K 0.11%
760,035
– –
MRSN
37
DELISTED
Mersana Therapeutics
MRSN
$464K 0.1%
62,697
-5,504
-8% -$48.4K
ATAI icon
38
AtaiBeckley Inc
ATAI
$2.68B
$431K 0.09%
196,858
– –
GUTS icon
39
Fractyl Health
GUTS
$111M
$347K 0.07%
214,236
– –
FTH
40
Faeth Therapeutics
FTH
$629M
$126K 0.03%
14,718
-1
-0% -$7
ARQT icon
41
PUT
Arcutis Biotherapeutics
ARQT
$3.18B
– –
-100,000
Closed -$1.25M
BDX icon
42
Becton Dickinson
BDX
$48.2B
– –
-203,965
Closed -$46.7M
INSP icon
43
Inspire Medical Systems
INSP
$1.74B
– –
-85,877
Closed -$13.7M
KROS icon
44
Keros Therapeutics
KROS
$221M
– –
-389,384
Closed -$3.97M
LIVN icon
45
LivaNova
LIVN
$4.2B
– –
-381,648
Closed -$15M
REGN icon
46
Regeneron Pharmaceuticals
REGN
$80.8B
– –
-12,261
Closed -$7.78M
SLNO
47
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-100,000
Closed -$6.5M
SWTX
48
DELISTED
SpringWorks Therapeutics
SWTX
– –
-758,533
Closed -$33.5M
VCYT icon
49
Veracyte
VCYT
$3.8B
– –
-762,225
Closed -$22.6M
1
2

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
DA
Dash Acquisitions Woodland Hills, California $480M AUM 4.07% 1-Year Est. Return
NQWM
Northwest Quadrant Wealth Management Bend, Oregon $481M AUM 13.55% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM

Catalio Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Catalio Capital Management held 49 positions worth $477M, up 16% from $411M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Catalio Capital Management deployed $35.2M of net new capital in Q2 2025, opening 12 new positions and adding to 8 existing holdings. Its largest new stake was Gilead Sciences: 226,875 shares worth $25.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Septerna Inc, an estimated $6.01M trimmed.

  • Catalio Capital Management's largest Q2 2025 buy was Gilead Sciences: 226,875 shares worth $25.2M.
  • Catalio Capital Management added most to Eli Lilly in Q2 2025, an estimated $23.5M increase.
  • Catalio Capital Management's biggest Q2 2025 reduction was Septerna Inc, cutting an estimated $6.01M.
  • Catalio Capital Management fully exited Becton Dickinson in Q2 2025, selling an estimated $46.7M.
  • Catalio Capital Management's ten largest holdings make up 63% of its $477M portfolio in Q2 2025.
  • Catalio Capital Management opened 12 new positions and closed 9 in Q2 2025.
  • Catalio Capital Management's portfolio value rose 16% quarter-over-quarter to $477M.

Based on Catalio Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.